Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia (Non PK Study)

NCT00937378 is registered in ClinicalTrials.gov with Serenity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00937378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00937378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia (Non PK Study)
Lead sponsor
Serenity Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2009
Completion date
August 31, 2010
Enrollment
326 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nocturia